{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"-% of subjects who achieve a complete response (CR) or partial response (CR) based on assessment of brain lesions\n\n* CR: Requires: complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; No new lesions; stable or improved nonenhancing (T2/FLAIR) lesions.; off corticosteroids (or on physiologic replacement doses only) and stable or improved clinically.\n* PR: Requires:• ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks. • No progression of nonmeasurable disease. • Stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; the corticosteroid dose at the time of the scan evaluation should be no greater than the dose at time of baseline scan. • Stable or improved clinically","groups":[{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG000","title":"Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG001","title":"Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG002","title":"Cohort C: NSCLC or Non-NSCLC w/Corticosteroids"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"There were not any participants enrolled in Cohort B or Cohort C.","reportingStatus":"POSTED","timeFrame":"Completion of treatment (estimated to be 6 months)","title":"Overall Response Rate of Intracranial Disease","type":"PRIMARY","unitOfMeasure":"Participants"}